ZA201905790B - Anti-lag-3 antibodies and uses thereof - Google Patents
Anti-lag-3 antibodies and uses thereofInfo
- Publication number
- ZA201905790B ZA201905790B ZA2019/05790A ZA201905790A ZA201905790B ZA 201905790 B ZA201905790 B ZA 201905790B ZA 2019/05790 A ZA2019/05790 A ZA 2019/05790A ZA 201905790 A ZA201905790 A ZA 201905790A ZA 201905790 B ZA201905790 B ZA 201905790B
- Authority
- ZA
- South Africa
- Prior art keywords
- lag
- antibodies
- autoimmune
- stimulating
- inflammatory
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2017/074365 WO2018152687A1 (en) | 2017-02-22 | 2017-02-22 | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |
| CN2017088570 | 2017-06-16 | ||
| PCT/CN2018/076940 WO2018153340A1 (en) | 2017-02-22 | 2018-02-22 | Anti-lag-3 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201905790B true ZA201905790B (en) | 2025-03-26 |
Family
ID=63253327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/05790A ZA201905790B (en) | 2017-02-22 | 2019-09-02 | Anti-lag-3 antibodies and uses thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10577421B2 (enExample) |
| EP (1) | EP3389702A4 (enExample) |
| JP (1) | JP6929951B2 (enExample) |
| KR (2) | KR102236259B1 (enExample) |
| CN (1) | CN109475617B (enExample) |
| AU (1) | AU2018226298B2 (enExample) |
| CA (1) | CA3053989C (enExample) |
| IL (1) | IL268734A (enExample) |
| NZ (1) | NZ756678A (enExample) |
| SG (1) | SG11201907561PA (enExample) |
| WO (1) | WO2018153340A1 (enExample) |
| ZA (1) | ZA201905790B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200037250A (ko) * | 2017-07-06 | 2020-04-08 | 메뤼스 엔.페. | 세포에 의해 발현되는 생물학적 활성을 조절하는 항체 |
| US12173070B2 (en) | 2018-08-21 | 2024-12-24 | Abl Bio Inc. | Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof |
| CN110066334B (zh) * | 2019-03-22 | 2020-03-10 | 南京医科大学 | 抗Galectin-3的全人源化单域抗体及应用 |
| CN112010976B (zh) * | 2019-05-29 | 2022-07-01 | 山东博安生物技术股份有限公司 | 抗lag3抗体及其用途 |
| CN110320367A (zh) * | 2019-05-30 | 2019-10-11 | 广州医科大学附属第一医院（广州呼吸中心） | 基于lag-3的诊断试剂盒及其在帕金森病诊断产品上的应用 |
| EP3985022A4 (en) * | 2019-06-14 | 2023-08-02 | ABL Bio, Inc. | BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ITS USE |
| EP3998286A4 (en) * | 2019-07-11 | 2023-04-26 | Wuhan Yzy Biopharma Co., Ltd. | QUAD VALUE SYMMETRIC BISPECIFIC ANTIBODIES |
| EP4039711A4 (en) * | 2019-07-23 | 2023-11-15 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-lag-3 bispecific antibody, preparation method therefor and use thereof |
| CN113004407B (zh) * | 2019-12-20 | 2022-11-11 | 广东菲鹏制药股份有限公司 | Lag3抗体及其应用 |
| CN113348182B (zh) * | 2019-12-30 | 2022-07-12 | 上海海路生物技术有限公司 | Lag-3抗体及其医药用途 |
| WO2021163989A1 (en) * | 2020-02-21 | 2021-08-26 | Yinnuolai Biotech Ltd. | Anti-baff receptor antibodies and uses thereof |
| CN116063473B (zh) * | 2020-05-19 | 2026-06-09 | 益科思特(北京)医药科技发展有限公司 | 抗新型冠状病毒Spike蛋白抗体及其应用 |
| CN111808192B (zh) * | 2020-06-05 | 2022-02-15 | 北京天广实生物技术股份有限公司 | 结合lag3的抗体及其用途 |
| CN112062832B (zh) * | 2020-09-24 | 2021-08-03 | 河南赛诺特生物技术有限公司 | Galectin-3抗原表位肽、抗原、抗体、杂交瘤细胞株及试剂盒 |
| WO2022109987A1 (en) * | 2020-11-27 | 2022-06-02 | Shanghai Benemae Pharmaceutical Corporation | Novel anti-lag3 antibodies and methods of making and using the same |
| CN116514972B (zh) | 2020-12-10 | 2023-10-27 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 |
| AU2022218137A1 (en) | 2021-02-03 | 2023-08-24 | Mozart Therapeutics, Inc. | Binding agents and methods of using the same |
| CN115490764B (zh) * | 2021-06-18 | 2025-06-03 | 佛山热休生物技术有限公司 | Lgals3的表位肽及所述表位肽与热休克蛋白的复合物 |
| WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
| US20250198990A1 (en) * | 2022-03-15 | 2025-06-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of Identifying Anti-LAG-3 Agents |
| CN115819595B (zh) * | 2023-01-03 | 2023-05-16 | 上海百英生物科技股份有限公司 | 一种抗lag3纳米抗体及其制备方法与应用 |
| WO2024189628A1 (en) * | 2023-03-16 | 2024-09-19 | Technion Research And Development Foundation Limited | Lag-3 inhibition for enhanced antiviral immune response |
| WO2024196072A1 (ko) * | 2023-03-20 | 2024-09-26 | 경북대학교 산학협력단 | Lag-3에 결합하는 펩타이드 및 이의 용도 |
| WO2025040080A1 (en) * | 2023-08-21 | 2025-02-27 | Beigene Switzerland Gmbh | Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy |
| WO2025128836A1 (en) * | 2023-12-13 | 2025-06-19 | Eli Lilly And Company | Lag-3 agonist antibodies |
| US20260158137A1 (en) | 2024-09-10 | 2026-06-11 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bcma inhibitors in combination with lag3 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR072999A1 (es) * | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| RS60538B1 (sr) * | 2013-03-15 | 2020-08-31 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 vezujući proteini |
| MX371187B (es) * | 2013-12-06 | 2020-01-22 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos. |
| EA201691765A1 (ru) * | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| MA41463A (fr) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CN114853891A (zh) * | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| PE20231958A1 (es) * | 2015-07-30 | 2023-12-06 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas |
-
2018
- 2018-02-22 WO PCT/CN2018/076940 patent/WO2018153340A1/en not_active Ceased
- 2018-02-22 AU AU2018226298A patent/AU2018226298B2/en active Active
- 2018-02-22 KR KR1020197014275A patent/KR102236259B1/ko active Active
- 2018-02-22 CA CA3053989A patent/CA3053989C/en active Active
- 2018-02-22 SG SG11201907561PA patent/SG11201907561PA/en unknown
- 2018-02-22 EP EP18733152.5A patent/EP3389702A4/en not_active Withdrawn
- 2018-02-22 NZ NZ756678A patent/NZ756678A/en unknown
- 2018-02-22 KR KR1020187022954A patent/KR102144317B1/ko active Active
- 2018-02-22 CN CN201880000932.2A patent/CN109475617B/zh active Active
- 2018-02-22 US US16/069,487 patent/US10577421B2/en active Active
- 2018-02-22 JP JP2019544658A patent/JP6929951B2/ja active Active
-
2019
- 2019-08-15 IL IL26873419A patent/IL268734A/en unknown
- 2019-09-02 ZA ZA2019/05790A patent/ZA201905790B/en unknown
- 2019-11-18 US US16/687,387 patent/US11414485B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190111894A (ko) | 2019-10-02 |
| US10577421B2 (en) | 2020-03-03 |
| WO2018153340A1 (en) | 2018-08-30 |
| CN109475617A (zh) | 2019-03-15 |
| KR20180113195A (ko) | 2018-10-15 |
| CA3053989A1 (en) | 2018-08-30 |
| EP3389702A4 (en) | 2019-08-14 |
| US20190225687A1 (en) | 2019-07-25 |
| AU2018226298A1 (en) | 2019-09-19 |
| NZ756678A (en) | 2023-02-24 |
| JP2020508303A (ja) | 2020-03-19 |
| CA3053989C (en) | 2024-10-29 |
| IL268734A (en) | 2019-10-31 |
| JP6929951B2 (ja) | 2021-09-01 |
| SG11201907561PA (en) | 2019-09-27 |
| US11414485B2 (en) | 2022-08-16 |
| AU2018226298B2 (en) | 2022-02-17 |
| KR102236259B1 (ko) | 2021-04-06 |
| US20200071403A1 (en) | 2020-03-05 |
| EP3389702A1 (en) | 2018-10-24 |
| CN109475617B (zh) | 2022-05-17 |
| KR102144317B1 (ko) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ756678A (en) | Anti-lag-3 antibodies and uses thereof | |
| PH12018500664A1 (en) | Anti-lag3 antibodies and uses thereof | |
| PH12020500078A1 (en) | Anti-ctla-4 antibodies and uses thereof | |
| PH12021550764A1 (en) | Trem2 stabilizing antibodies | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| MY203971A (en) | Anti-lag-3 antibodies and compositions | |
| MX2019002867A (es) | Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1. | |
| EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
| MX2021007939A (es) | Porciones de union a claudina 18.2 y usos de estas. | |
| PH12021551484A1 (en) | Antibodies binding to cd3 | |
| PH12018501778A1 (en) | Antibodies to tigit | |
| NZ737796A (en) | Anti-tau antibodies and methods of use | |
| MY185845A (en) | Icos binding proteins | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| GEAP202014811A (en) | Ctla4 binders | |
| JOP20190236A1 (ar) | أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد | |
| PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
| CN110520441B8 (zh) | 抗TGF-β抗体及其用途 | |
| MX2018006973A (es) | Anticuerpos anti-cd73 humanizados. | |
| ZA201807920B (en) | Anti¿gitr antibodies and uses thereof | |
| SG10201907161YA (en) | Antibodies directed against lymphocyte activation gene 3 (lag-3) | |
| WO2015132675A3 (en) | Methods and compositions for modifying the immune response | |
| MX2022006073A (es) | Metodos para utilizar anticuerpos anti-trem2. | |
| WO2017019957A3 (en) | Binding proteins and methods of use thereof | |
| WO2019094533A8 (en) | Angptl8-binding agents and methods of use thereof |